Avelumab Plus Axitinib

Neoadjuvant avelumab plus axitinib active in high-risk RCC | Axel Bex

Medicine Matters oncology

Avelumab plus axitinib improves survival in advanced renal-cell carcinoma patients

infocusrx today

Avelumab plus axitinib shows good efficacy for OS and PFS in aRCC patients

JAVELIN Renal 101: avelumab plus axitinib improve PFS for advanced renal cell cancer

Dr. Choueiri on Avelumab Plus Axitinib in mRCC

Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC

Exploring the Combination of First-Line Avelumab/Axitinib in HCC

Targeted Oncology

Pembrolizumab/Axitinib and Avelumab/Axitinib combo for RCC

Dr. Shuch on Caveats of Avelumab/Axitinib Combination in RCC

Dr. Rini on Managing the Toxicity of Pembrolizumab Plus Axitinib in mRCC

JAVELIN Renal 101: combination approach for advanced RCC patients | Laurence Albiges

Medicine Matters oncology

Final results of avelumab and axitinib in RCC in the JAVELIN Renal 101 trial

Avelumab and axitinib for the treatment of advanced RCC

Combining avelumab and axitinib in advanced renal cell carcinoma (RCC)

Dr. Rini on Pembrolizumab Plus Axitinib in RCC

Avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma

Dr. Choueiri Discusses Avelumab/Axitinib Data in RCC

TIDE-A: avelumab and intermittent axitinib in metastatic renal cell carcinoma

Kidney cancer updates: avelumab/axitinib, pembro/axitinib, bevacizumab/atezo & ipilimumab/nivo

Study on avelumab and axitinib vs sunitinib in the treatment of advanced renal cell carcinoma